Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acrivon Therapeutics, Inc. - Common Stock
(NQ:
ACRV
)
6.190
-0.040 (-0.64%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
26,616
Open
6.230
Bid (Size)
5.800 (1)
Ask (Size)
7.590 (1)
Prev. Close
6.230
Today's Range
6.130 - 6.320
52wk Range
3.190 - 11.90
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 13, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
October 17, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Performance
YTD
+23.55%
+23.55%
1 Month
-15.78%
-15.78%
3 Month
-14.74%
-14.74%
6 Month
+7.47%
+7.47%
1 Year
+23.55%
+23.55%
More News
Read More
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
October 11, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
September 14, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
September 10, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
September 09, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 25, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 24, 2024
Via
Benzinga
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
April 24, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
April 16, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
April 10, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
April 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 09, 2024
Via
Benzinga
Dow Dips 150 Points; Laser Photonics Shares Spike Higher
April 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Rail Vision (RVSN) Stock Up 17% Today?
April 09, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
April 09, 2024
Via
InvestorPlace
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
April 09, 2024
Via
Benzinga
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings
April 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.